Developer docs
API playgroundTry for free, no card

Search company profiles

Steri-Pharma

Full company profile

uuid000ccj8

Namestring
Steri-Pharma
Legal namestring
Steri-Pharma
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Steri-Pharma is a privately held pharmaceutical manufacturer specializing in sterile human antibiotics, headquartered at 429 So. West Street, Syracuse, NY. The company operates a single GMP-compliant manufacturing facility of more than 70,000 square feet, including a 19,000 square foot expansion adding sterile production rooms, filling rooms, and warehouse capacity. Operations encompass regulated research, manufacturing, testing, and distribution under a global quality management system, with distribution approvals in 40 countries across North America, Europe, Latin America, and Asia.

The company's product portfolio is concentrated in one category — human sterile antibiotics — supplied to global pharmaceutical distributors via B2B wholesale channels. Pricing, contract structures, and distributor identities are not publicly disclosed. Steri-Pharma positions itself on regulatory compliance, product quality, and reliable delivery supported by climate-controlled storage and advanced transport logistics.

Steri-Pharma is independently owned with no disclosed parent company, investors, or board composition. The company maintains an active website and recruits across quality, production, maintenance, accounting, HR, and engineering functions via ADP. No revenue, headcount trend, funding history, or leadership information is publicly available, and the source material contains no record of patents, partnerships, awards, or AI/ML capabilities.

Short descriptiontext

Steri-Pharma is a privately held, GMP-compliant pharmaceutical manufacturer of sterile human antibiotics, operating from a 70,000+ sq ft facility in Syracuse, NY, and distributing to pharmaceutical wholesalers across 40 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSyracuse, United States
HQ citystring
Syracuse
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile antibiotics, pharmaceutical manufacturing, human antibiotics, generic drug manufacturing, GMP pharmaceutical production
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Steri-Pharma generates revenue through the manufacture and sale of sterile human antibiotics to global pharmaceutical markets and distributors across 40 approved countries.

steri-pharma.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Steri-Pharma manufactures and distributes sterile human antibiotics from a centralized GMP-compliant facility in Syracuse, New York. The company operates a manufacturing footprint of more than 70,000 square feet (with a 19,000 square foot expansion for sterile production, filling rooms, and warehouse space) and supplies its antibiotic products to pharmaceutical distributors across 40 approved countries in North America, Europe, Latin America, and Asia.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Steri-Pharma is a single-product pharmaceutical company specializing in the manufacturing and global distribution of human sterile antibiotics. The company operates from one centralized manufacturing facility in Syracuse, NY with a footprint of over 70,000 square feet plus a 19,000 square foot expansion. Their product portfolio consists of human anti-biotics distributed to 40 approved countries across North America, Europe, Latin America, and Asia.

Product and service1 record
1Human Sterile Antibiotics
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global generic injectable pharmaceutical manufacturer with a large sterile injectables portfolio including antibiotics; most directly comparable to Steri-Pharma in product category, B2B distributor model, and international regulatory footprint.

TypeDirect peer
Description

US-based specialty pharmaceutical company focused on injectable and intranasal products including sterile antibiotics; comparable in scale, single-product/specialty focus, and regulatory-driven competitive positioning.

TypeDirect peer
Description

Specialty manufacturer of anti-infective sterile injectable pharmaceuticals with global distribution; directly comparable product portfolio (sterile antibiotics) and B2B distribution model.

TypeDirect peer
Description

US-based specialty injectable pharmaceutical company with a portfolio of generic injectable products including antibiotics; comparable in product category, customer base (hospital/distributor), and regulatory-driven operating model.

5Hospira (Pfizer Injectables)
TypeBroad incumbent
Description

Largest US sterile injectable manufacturer prior to Pfizer acquisition; overlaps directly with Steri-Pharma's product category and B2B distribution model but operates as part of Pfizer's broader portfolio at much greater scale.

TypeBroad incumbent
Description

Global pharmaceutical company specializing in injectable generic drugs and infusion solutions including sterile antibiotics; comparable product category and global distribution, but operates as part of the larger Fresenius Group.

TypeBroad incumbent
Description

Global generic pharmaceutical manufacturer with a significant sterile injectable portfolio including antibiotics; comparable in product category and global distribution across regulated markets.

TypeBroad incumbent
Description

Indian-headquartered global generic pharmaceutical company with a large injectable antibiotics portfolio; comparable product category and global B2B distribution, though at substantially larger scale.

9Sandoz (Novartis)
TypeBroad incumbent
Description

Global leader in generic pharmaceuticals including a substantial sterile injectable antibiotics business; comparable product category and international regulatory footprint, operating at significantly larger scale.

TypeBroad incumbent
Description

Global generic pharmaceutical manufacturer with sterile injectable products including antibiotics; comparable in B2B distribution model and regulated international markets, though operating at much larger scale across multiple therapeutic areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Steri-Pharma

Pharmaceutical Manufacturingsteri-pharma.com

Steri-Pharma is a privately held, GMP-compliant pharmaceutical manufacturer of sterile human antibiotics, operating from a 70,000+ sq ft facility in Syracuse, NY, and distributing to pharmaceutical wholesalers across 40 countries.

What Steri-Pharma does

Steri-Pharma is a privately held pharmaceutical manufacturer specializing in sterile human antibiotics, headquartered at 429 So. West Street, Syracuse, NY. The company operates a single GMP-compliant manufacturing facility of more than 70,000 square feet, including a 19,000 square foot expansion adding sterile production rooms, filling rooms, and warehouse capacity. Operations encompass regulated research, manufacturing, testing, and distribution under a global quality management system, with distribution approvals in 40 countries across North America, Europe, Latin America, and Asia.

The company's product portfolio is concentrated in one category — human sterile antibiotics — supplied to global pharmaceutical distributors via B2B wholesale channels. Pricing, contract structures, and distributor identities are not publicly disclosed. Steri-Pharma positions itself on regulatory compliance, product quality, and reliable delivery supported by climate-controlled storage and advanced transport logistics.

Steri-Pharma is independently owned with no disclosed parent company, investors, or board composition. The company maintains an active website and recruits across quality, production, maintenance, accounting, HR, and engineering functions via ADP. No revenue, headcount trend, funding history, or leadership information is publicly available, and the source material contains no record of patents, partnerships, awards, or AI/ML capabilities.

Steri-Pharma firmographics

Firmographics
Name
Steri-Pharma
Legal name
Steri-Pharma
Website
https://steri-pharma.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Steri-Pharma is a privately held, GMP-compliant pharmaceutical manufacturer of sterile human antibiotics, operating from a 70,000+ sq ft facility in Syracuse, NY, and distributing to pharmaceutical wholesalers across 40 countries.
Ownership category
akta.pro rank

Where Steri-Pharma is headquartered

Location

Headquarters

HQ city
Syracuse
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Steri-Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D

Revenue model

  1. Pharmaceutical Product Sales: Steri-Pharma generates revenue through the manufacture and sale of sterile human antibiotics to global pharmaceutical markets and distributors across 40 approved countries.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Steri-Pharma product offering

Product offering

Core offering

Steri-Pharma manufactures and distributes sterile human antibiotics from a centralized GMP-compliant facility in Syracuse, New York. The company operates a manufacturing footprint of more than 70,000 square feet (with a 19,000 square foot expansion for sterile production, filling rooms, and warehouse space) and supplies its antibiotic products to pharmaceutical distributors across 40 approved countries in North America, Europe, Latin America, and Asia.

Product overview

Steri-Pharma is a single-product pharmaceutical company specializing in the manufacturing and global distribution of human sterile antibiotics. The company operates from one centralized manufacturing facility in Syracuse, NY with a footprint of over 70,000 square feet plus a 19,000 square foot expansion. Their product portfolio consists of human anti-biotics distributed to 40 approved countries across North America, Europe, Latin America, and Asia.

Differentiator

Problem solved

Functional benefit

Products and services

  • Human Sterile Antibiotics

Companies that use Steri-Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Steri-Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Steri-Pharma partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves2 records

Expansion highlights3 records

Steri-Pharma competitors and assessment

Company assessment

Direct peers

  • Hikma Pharmaceuticals: Global generic injectable pharmaceutical manufacturer with a large sterile injectables portfolio including antibiotics; most directly comparable to Steri-Pharma in product category, B2B distributor model, and international regulatory footprint.
  • Amphastar Pharmaceuticals: US-based specialty pharmaceutical company focused on injectable and intranasal products including sterile antibiotics; comparable in scale, single-product/specialty focus, and regulatory-driven competitive positioning.
  • Xellia Pharmaceuticals: Specialty manufacturer of anti-infective sterile injectable pharmaceuticals with global distribution; directly comparable product portfolio (sterile antibiotics) and B2B distribution model.
  • Sagent Pharmaceuticals: US-based specialty injectable pharmaceutical company with a portfolio of generic injectable products including antibiotics; comparable in product category, customer base (hospital/distributor), and regulatory-driven operating model.

Broad incumbents

  • Hospira (Pfizer Injectables): Largest US sterile injectable manufacturer prior to Pfizer acquisition; overlaps directly with Steri-Pharma's product category and B2B distribution model but operates as part of Pfizer's broader portfolio at much greater scale.
  • Fresenius Kabi: Global pharmaceutical company specializing in injectable generic drugs and infusion solutions including sterile antibiotics; comparable product category and global distribution, but operates as part of the larger Fresenius Group.
  • Dr. Reddy's Laboratories: Global generic pharmaceutical manufacturer with a significant sterile injectable portfolio including antibiotics; comparable in product category and global distribution across regulated markets.
  • Aurobindo Pharma: Indian-headquartered global generic pharmaceutical company with a large injectable antibiotics portfolio; comparable product category and global B2B distribution, though at substantially larger scale.
  • Sandoz (Novartis): Global leader in generic pharmaceuticals including a substantial sterile injectable antibiotics business; comparable product category and international regulatory footprint, operating at significantly larger scale.
  • Lupin Pharmaceuticals: Global generic pharmaceutical manufacturer with sterile injectable products including antibiotics; comparable in B2B distribution model and regulated international markets, though operating at much larger scale across multiple therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Steri-Pharma compliance and trust

Trust signal

Compliance1 record

Steri-Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Steri-Pharma leadership team

Management profile

Number of profiles

Steri-Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Steri-Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Steri-Pharma

What does Steri-Pharma do?

Steri-Pharma manufactures and distributes sterile human antibiotics from a centralized GMP-compliant facility in Syracuse, New York. The company operates a manufacturing footprint of more than 70,000 square feet (with a 19,000 square foot expansion for sterile production, filling rooms, and warehouse space) and supplies its antibiotic products to pharmaceutical distributors across 40 approved countries in North America, Europe, Latin America, and Asia.

Is Steri-Pharma a public or private company?

Steri-Pharma is a private company. It is classified as unknown and is currently operating.

When was Steri-Pharma founded?

Steri-Pharma was founded in 2018. It employs 51 to 100 people.

Where is Steri-Pharma based?

Steri-Pharma is headquartered in Syracuse, United States, in the North America region.

How does Steri-Pharma make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Steri-Pharma's main competitors?

Direct peers on record are Hikma Pharmaceuticals, Amphastar Pharmaceuticals, Xellia Pharmaceuticals and Sagent Pharmaceuticals. Broad incumbents are Hospira (Pfizer Injectables), Fresenius Kabi, Dr. Reddy's Laboratories, Aurobindo Pharma, Sandoz (Novartis) and Lupin Pharmaceuticals.

Does Steri-Pharma have an API?

No public API is recorded for Steri-Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales